<DOC>
	<DOCNO>NCT01572038</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm , Phase IIIb study evaluate safety tolerability pertuzumab combination trastuzumab ( Herceptin ) taxane ( docetaxel , paclitaxel nab-paclitaxel ) first-line treatment participant metastatic locally recurrent HER2-positive breast cancer . Participants receive pertuzumab intravenously ( IV ) trastuzumab ( Herceptin ) IV plus taxane cycle 3 week predefined study end , unacceptable toxicity , withdrawal consent , disease progression , death , whichever occur first .</brief_summary>
	<brief_title>A Study Pertuzumab Combination With Trastuzumab ( Herceptin ) Taxane First-Line Treatment Participants With Human Epidermal Growth Factor 2 ( HER2 ) -Positive Advanced Breast Cancer ( PERUSE )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast metastatic locally recurrent disease amenable curative resection HER2positive breast cancer Eastern cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 LVEF least 50 percent ( % ) Previous systemic nonhormonal anticancer therapy metastatic locally recurrent disease Diseasefree interval completion adjuvant neoadjuvant systemic nonhormonal treatment recurrence less equal ( &lt; /= ) 6 month Previous approve investigative antiHER2 agent breast cancer treatment set , except trastuzumab and/or lapatinib adjuvant neoadjuvant set Disease progression receive trastuzumab and/or lapatinib adjuvant neoadjuvant set History persistent Grade 2 high ( National Cancer Institute Common Toxicity Criteria [ NCICTC ] , Version 4.0 ) hematological toxicity result previous adjuvant neoadjuvant therapy Central nervous system ( CNS ) metastases Current peripheral neuropathy Grade 3 great ( NCICTC , version 4.0 ) History malignancy within last 5 year prior first study drug administration , except carcinoma situ cervix basal cell carcinoma Inadequate bone marrow , liver renal function Uncontrolled hypertension Hepatitis B , hepatitis C Human Immunodeficiency Virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>